Botanical Blends and 7-OH Alternatives: What’s Really in These New Products?

Key Points

• Botanical blends are an expanding product category. Following restrictions on kratom and concentrated 7-hydroxymitragynine (7-OH), retailers have increasingly promoted Cat’s Claw, kava, kanna, mushroom products, and proprietary formulations as alternatives.
• Not every botanical blend contains an opioid. Genuine plant extracts and chemically manufactured opioids are very different substances. Their ingredients, effects, and safety profiles should not be treated as interchangeable.
• Some Cat’s Claw products have contained undisclosed opioids. Utah authorities confirmed mitragynine pseudoindoxyl (MGPI) and MGM-15 in tested Buzzers Cat’s Claw tablets. A separate California investigation identified MGM-15 in a Script Botanicals product associated with a fatal overdose.
• New brands and compounds require individual scrutiny. Buzzers, Homiez, Fuzziez, Shift, KLAZ, Thizziez, Mitraxidine, nano-tech mitragynine, and other products have appeared in the evolving marketplace, but the evidence differs considerably between them.
• Other substances are being discussed as replacements. Akuamma, Corydalis, 13-OH-labeled products, blue lotus, kratom alkaloid concentrates, tianeptine, phenibut, and experimental synthetic opioids have all entered conversations about alternatives to 7-OH.
• A laboratory certificate is not a guarantee of safety. Testing for mitragynine and 7-OH does not automatically exclude MGM-15, MGPI, or other undisclosed psychoactive substances.
• How Brooks Helps: Brooks Healing Center provides medical detox, residential treatment, medications for opioid use disorder (MOUD), PHP, and continued recovery support for people struggling with opioids, kratom-derived compounds, and other substances.

---

Walk into certain smoke shops or visit an online botanical retailer in 2026, and the products look different from what was being sold a year ago. Where concentrated 7-OH tablets and kratom extracts once dominated the shelves, consumers are now encountering products labeled Cat’s Claw, proprietary botanical extract, advanced alkaloid blend, nano-tech mitragynine, and even ketone tablets.

Some promise relaxation. Others use language suggesting stronger effects, improved absorption, or a legal alternative to previously available products.

The name on the packaging, however, doesn’t necessarily explain what someone is taking.

This became particularly concerning when public-health investigators identified potent opioid compounds in products marketed under ordinary botanical names. In July 2026, Utah authorities confirmed MGM-15 and mitragynine pseudoindoxyl in tested Buzzers Cat’s Claw tablets. In October, San Francisco officials reported a fatal overdose involving MGM-15 found in a Script Botanicals × Maui Labs product.

These findings raise an important question: Are botanical blends genuinely different herbal products, or are some manufacturers simply replacing familiar opioid names with unfamiliar ones?

The answer depends entirely on the product.

Some are legitimate botanical preparations with no established opioid activity. Others contain concentrated kratom alkaloids, proprietary combinations, or chemically manufactured substances with powerful effects on opioid receptors.

Understanding those differences matters, particularly for individuals who have developed dependence on 7-OH and are considering another product to manage withdrawal.

What Are Botanical Blends?

Botanical blends are products containing one or more plant-derived ingredients, often combined into tablets, capsules, liquids, powders, or other preparations.

The term is broad. It does not identify a specific chemical formulation, pharmacological effect, or manufacturing standard.

In traditional supplement markets, a botanical blend might simply combine herbal extracts intended for general wellness.

In the newer psychoactive-product market, however, the term has increasingly appeared alongside products promoted for relaxation, mood enhancement, stimulation, or experiences resembling those associated with kratom and concentrated 7-OH.

There is also an online retailer operating under the name Botanical Blends that markets products described as kratom-free botanical alternatives.

The company lists several Cat’s Claw-associated brands, including Buzzers, Homiez, Fuzziez, and Shift. It advertises third-party testing and claims its listed products contain no detectable mitragynine or 7-OH in the tests it publishes.

Those are the retailer’s representations. They do not establish that every product has been tested for every opioid-active compound or that different manufacturing batches have identical compositions.

The important distinction is between a product’s advertised category and its actual chemical ingredients.

Why Are Botanical Blends Becoming Popular?

The changing market is closely connected to restrictions on kratom-derived substances.

Tennessee prohibited the possession, manufacture, and sale of kratom beginning July 1, 2026, under Matthew Davenport’s Law.

Federal authorities have also taken action against concentrated 7-OH and several related compounds.

On August 26, 2026, the Drug Enforcement Administration temporarily placed MGM-15, MGM-16, and mitragynine pseudoindoxyl into Schedule I.

In October, federal authorities announced updated scheduling proposals intended to distinguish trace amounts of certain alkaloids in natural kratom from intentionally concentrated or enhanced formulations.

As products disappeared from shelves, consumers began encountering new brands, botanical names, and proprietary blends.

The marketplace’s response doesn’t mean every replacement is illicit or dangerous. But it creates an environment where new labels can appear faster than reliable clinical research.

Botanical Blends and 7-OH Alternatives: Comparison Table

The following table covers major products, substances, and categories appearing in discussions about 7-OH alternatives.

These categories should not be interpreted as equivalent in potency, legality, or clinical risk.

1. Cat’s Claw Blends: Buzzers, Homiez, Fuzziez, Shift, KLAZ, and Script Botanicals

Cat’s Claw has become one of the most visible botanical names in the changing 7-OH marketplace.

Genuine Cat’s Claw generally refers to plants such as Uncaria tomentosa, a woody vine native to Central and South America.

The plant contains oxindole alkaloids, including mitraphylline and related compounds. These are different from the primary opioid-active alkaloids associated with kratom.

Ordinary Cat’s Claw should not be assumed to produce effects resembling concentrated 7-OH.

The concern is that some commercial products have used Cat’s Claw branding while containing substances not ordinarily associated with the plant.

Buzzers Cat’s Claw Tablets

Buzzers is among the most significant examples because of confirmed government laboratory findings.

On July 30, 2026, the Utah Department of Agriculture and Food reported that tested Buzzers Cat’s Claw products contained:

• Mitragynine pseudoindoxyl (MGPI)
• MGM-15, also called dihydro-7-hydroxymitragynine

Both compounds interact with opioid receptors and differ substantially from conventional Cat’s Claw constituents.

Utah officials connected the investigated products with severe health incidents and a death investigation.

An important distinction is that the investigation established the composition of specific tested products, not every Buzzers tablet ever manufactured.

Nevertheless, the findings provide strong evidence that botanical branding can obscure significant opioid-related risks.

Homiez Botanical Tablets

Homiez was also identified in a July 2026 Utah Poison Control warning concerning potentially adulterated products marketed as Cat’s Claw or kava.

The poison center reported severe overdoses associated with the broader category and warned that such products might contain kratom-related opioid compounds.

However, the publicly described confirmatory findings for Buzzers should not automatically be applied to every Homiez product.

The precise ingredients and concentrations in a particular Homiez formulation require product-specific evidence.

Fuzziez and Shift Cat’s Claw Products

Fuzziez and Shift are additional brands appearing in the Cat’s Claw marketplace.

Retail listings describe Fuzziez botanical sachets and Shift tablets, with products advertised as kratom-free botanical preparations.

The available information does not establish that these brands contain the same substances detected in investigated Buzzers products.

It also does not establish their clinical safety, effects, or long-term dependence potential.

Without adequate characterization of the active ingredients, claims about superior safety or similarity to 7-OH should remain unverified.

KLAZ Cat’s Claw Tablets

KLAZ is particularly relevant to Tennessee.

During August 2026, the Warren County Prevention and Intervention Coalition documented KLAZ and Buzzers Cat’s Claw products appearing in McMinnville-area stores following the state’s kratom restrictions.

The coalition’s observations confirmed the products were appearing in the local retail market. They did not establish that every product observed had been independently tested for opioid compounds.

For families in Middle Tennessee, this is an example of how quickly unfamiliar products can become locally available.

Script Botanicals and Maui Labs

Another serious finding emerged in California.

On October 21, 2026, San Francisco public-health officials reported a fatal overdose involving MGM-15.

Investigators identified the compound in biological specimens from the person who died and in material associated with a Script Botanicals × Maui Labs product marketed as Cat’s Claw.

Consumers have also reported unusual reactions involving some Script Botanicals products, including severe anxiety, excessive sweating, and withdrawal-like symptoms.

Those reports do not establish a common cause, and the chemical composition of every implicated batch has not been verified.

Some online discussions have mentioned a purported compound called hydrogenated mitraphylline. However, its exact chemical identity, presence in the products, and relationship to those reactions remain insufficiently established.

The confirmed MGM-15 finding and unverified hydrogenated mitraphylline claims should not be confused.

Read our focused article on Script Botanicals Cat’s Claw, reported reactions, and the MGM-15 finding.

Learn more in our investigations of Cat’s Claw products marketed as alternatives to 7-OH and Buzzers vs. Thizziez tablets.

2. Mitragynine, Nano-Tech Products, and Proprietary Kratom Blends

Another group of products emphasizes mitragynine rather than concentrated 7-OH.

Mitragynine is the primary psychoactive alkaloid found in kratom leaves. It interacts with opioid receptors but has a different pharmacological profile from 7-OH and manufactured opioid derivatives.

Commercial products may contain concentrated mitragynine, full-spectrum kratom extracts, or combinations with additional ingredients.

Nano-Tech Mitragynine

Some products advertise nano-tech processing, suggesting that smaller particles or other delivery technologies improve absorption.

7Stax, for example, has marketed chewable Nano Tech Mitragynine tablets.

Although pharmaceutical nanotechnology can influence drug delivery, the word “nano” does not establish a product’s actual absorption rate or clinical effects.

More concerningly, independent laboratory testing of a submitted 7Stax 80 mg Raspberry Nano Tech tablet in March 2026 measured approximately 23.10 mg of mitragynine and detected 17.64 mg of MGM-15.

The laboratory result applies to that submitted sample, not every current formulation or production batch.

It demonstrates why consumers should evaluate product-specific testing rather than assuming a product contains only its advertised primary ingredient.

Read our detailed review of nano-tech mitragynine products and the 7Stax laboratory findings.

Mitraxidine and BARS Tablets

Mitraxidine is another name appearing in the market for alternatives to concentrated 7-OH.

BARS markets Mitraxidine as a proprietary kratom-derived formulation.

The company describes its products as excluding certain compounds, including 7-OH, MGPI, MGM-15, and MGM-16.

However, Mitraxidine is a proprietary formulation name, not a single established chemical identity.

The name alone does not establish the precise contents, pharmacological effects, or comparative safety of the tablets.

BARS has also used segmented, rectangular tablet designs resembling familiar prescription pill formats. That appearance does not mean the products contain alprazolam or have the same medical effects as prescription medication.

Brooks examines the marketing and ingredient questions in What Is Mitraxidine? The 7-OH Alternative.

3. MGPI, MGM-15, MGM-16, and Smax Pseudo-DHM

This group deserves particular attention because it includes compounds that act directly on opioid receptors.

These are not simply herbal blends intended for general wellness.

Mitragynine Pseudoindoxyl (MGPI)

Mitragynine pseudoindoxyl, sometimes called pseudoindoxyl or pseudo, is a potent opioid-active compound associated with kratom alkaloid chemistry.

It has been investigated in pharmacological research and identified in certain commercially marketed products.

Its appearance in tested Buzzers tablets demonstrated that products claiming not to contain ordinary kratom or 7-OH can still contain other kratom-related opioids.

The FDA and HHS have raised concerns about its dependence and withdrawal potential.

For a more detailed comparison, read Mitragynine Pseudoindoxyl vs. 7-Hydroxymitragynine.

MGM-15 and MGM-16

MGM-15 and MGM-16 are manufactured compounds related to 7-OH.

MGM-15 is also called dihydro-7-hydroxymitragynine and may be described in certain product discussions using terms such as DHM.

MGM-16 is another chemically modified compound investigated for potent opioid activity.

Research comparing MGM-16 with related compounds has demonstrated substantial opioid receptor activity in experimental models. However, animal and laboratory findings do not establish safe human dosing or a predictable clinical response.

Both substances were included in federal Schedule I controls beginning August 26, 2026.

Brooks has explored these separately in our articles on MGM-15 and MGM-16 vs. MGM-15.

Smax Pseudo-DHM

Smax Pseudo-DHM is another example of the increasingly complicated product market.

In September 2026, the American Kratom Association publicized law-enforcement records reportedly identifying Smax Pseudo-DHM tablets as products purchased by two University of Mississippi students before their deaths.

Descriptions of the product identify a combination involving pseudoindoxyl, MGM-15, and 7-OH.

However, records describing a purchase do not independently establish that the products caused the deaths. Establishing that relationship requires appropriate toxicological and investigative findings.

The important concern is the marketed combination of multiple potent opioid-active compounds.

A product containing several related substances may create effects and risks that cannot be reliably predicted by examining only one ingredient.

It also reinforces why treating all kratom-associated products as chemically equivalent is inaccurate.

4. Akuamma: A Botanical Alternative With Opioid-Active Alkaloids

Akuamma is derived from the seeds of Picralima nitida, a tree native to West Africa.

Unlike ordinary Cat’s Claw, akuamma contains several naturally occurring alkaloids that have demonstrated interactions with opioid receptors in laboratory research.

These include:

• Akuammine
• Akuammidine
• Pseudoakuammigine
• Akuammicine

Researchers have studied these alkaloids and chemically modified derivatives for potential pharmacological applications.

Some experimental modifications have produced compounds with substantially greater opioid receptor activity than their parent molecules.

However, those findings should not be applied directly to ordinary akuamma seed preparations.

Human research is insufficient to establish that akuamma safely relieves opioid withdrawal, treats pain, or prevents addiction.

Nor is there enough evidence to define an akuamma-specific dependence or withdrawal syndrome.

People considering akuamma as a substitute for kratom or concentrated 7-OH should understand that plant origin does not eliminate pharmacological risk.

We explore this research in Akuamma vs. Kratom: Opioid Effects, Dependence, and Risks.

5. Kava, Kanna, Blue Lotus, and Corydalis

These plants are often grouped together in marketing discussions about botanical alternatives, but their chemistry differs considerably.

They should not be treated as equivalent to one another or to concentrated opioid-active compounds.

Kava

Kava comes from Piper methysticum, a plant traditionally used in the South Pacific.

Its active compounds are known as kavalactones.

Kava can have calming and sedating effects, but its pharmacology differs from the opioid activity associated with 7-OH.

The National Center for Complementary and Integrative Health reports that certain kava products have been associated with liver injury, including rare severe cases.

Kava may also interact dangerously with alcohol, benzodiazepines, and other sedating substances.

Separate from genuine kava, Utah Poison Control has warned that some products marketed using kava or Cat’s Claw branding may contain undisclosed opioid-active substances.

Those concerns should not be interpreted as evidence that ordinary kava naturally contains MGM-15 or pseudoindoxyl.

Read our investigation, Fake Kava? Hidden Opioids in Kava-Labeled Products.

Kanna

Kanna comes from Sceletium tortuosum, a South African plant containing alkaloids such as mesembrine and mesembrenone.

These compounds have been investigated for their effects on serotonin signaling and other neurological pathways.

Authentic kanna is psychoactive, but it does not have an established opioid mechanism comparable to 7-OH.

Its effects, potential drug interactions, and long-term safety remain incompletely characterized.

Particular caution is warranted when combining psychoactive serotonin-active products with prescription medications that influence serotonin.

Brooks provides additional information in What Is Kanna? Effects, Risks, and the New Botanical Market.

Blue Lotus

Blue lotus, commonly associated with Nymphaea caerulea, has gained attention in markets selling herbal products for relaxation or altered states of consciousness.

Its chemical constituents include aporphine-related alkaloids, although concentrations can vary substantially between commercial preparations.

Human research is limited, and the composition of concentrated extracts is often poorly standardized.

The fact that a product comes from a flower does not establish predictable psychoactive effects.

Brooks previously covered its appearance in the Tennessee market in Blue Lotus in Tennessee: Alternatives After Kratom and 7-OH Restrictions.

Corydalis and Products Marketed as 13-OH

Corydalis is another botanical appearing in formulations marketed alongside kratom alternatives.

Certain preparations are derived from Corydalis yanhusuo, a plant containing alkaloids such as tetrahydropalmatine.

Some commercial products use the term “13-OH Corydalis” and promote the ingredient as part of a proprietary formulation.

However, that marketing designation does not automatically establish a standardized chemical identity, pharmacological effect, or clinically tested formulation.

The name 13-OH should not be confused with 7-OH simply because both contain the abbreviation “OH.”

They are not established as interchangeable substances.

Products such as Tempo and Acend have been marketed with combinations involving kratom extracts, Corydalis, kanna, or additional active ingredients.

For combination products, research on one individual ingredient cannot establish the safety of the finished mixture.

6. Thizziez and Other Proprietary Ketone Blends

Thizziez represents another category of products that cannot be understood from botanical terminology alone.

Retail descriptions advertise Thizziez tablets containing a proprietary ketone blend, sometimes described as 3,000 mg per tablet.

The word “ketone” identifies a broad chemical structural feature, not one specific psychoactive compound.

A laboratory report published for certain Thizzies-branded samples found no detectable amounts of several screened kratom, mushroom, and cannabinoid-related substances.

However, the reviewed report did not fully identify the proprietary blend or establish its pharmacological effects.

It also did not specifically establish the absence of every emerging synthetic opioid.

There is insufficient evidence to conclude that Thizziez has the same ingredients as the Buzzers products investigated in Utah.

The difference between a documented adulteration finding and an unidentified proprietary formulation matters.

Neither should be treated as proof that an unrelated product is safe.

For the detailed comparison, read Buzzers vs. Thizziez: Ingredients, Opioid Risks, and What Testing Shows.

7. Mushroom Blends, Amanita Products, and Other Herbal Alternatives

Mushroom products are another category appearing in the broader botanical marketplace.

However, the word “mushroom” can describe products with very different chemical contents.

Functional mushrooms such as lion’s mane, reishi, cordyceps, chaga, and turkey tail are frequently sold as wellness supplements.

These should not automatically be confused with products containing muscimol, psilocin, or other psychoactive compounds.

Amanita muscaria, for example, contains substances such as muscimol and ibotenic acid.

The FDA has warned that Amanita muscaria and certain associated constituents do not meet the safety standard for use in conventional foods.

The agency also investigated illnesses associated with Diamond Shruumz-branded products in 2024, finding multiple psychoactive substances across analyzed samples.

These findings illustrate the risks of products marketed using broad descriptions that do not clearly explain their actual chemistry.

Additional botanicals sometimes discussed in relaxation or kratom-alternative markets include California poppy, wild dagga, passionflower, valerian, and similar herbal preparations.

These plants are not equivalent to 7-OH, and there is no reliable clinical evidence establishing them as treatments for opioid dependence or withdrawal.

A product marketed as natural relaxation support should not be assumed to replace the effects of an opioid-active substance.

8. What About 9-OH, MGM-9, and Other Emerging Names?

As the marketplace changes, consumers may encounter additional names and abbreviations, including references to 9-OH, MGM-9, or other purportedly modified alkaloids.

These names require particular caution.

Unlike established chemical identities such as 7-hydroxymitragynine or MGM-15, some commercial shorthand does not clearly identify a specific, independently characterized substance.

Without an unambiguous chemical structure, verified ingredient testing, and reliable research, it is not possible to establish:

• Whether the named compound is a distinct chemical substance
• Whether it occurs naturally or is manufactured
• Which receptors it interacts with
• Whether it produces opioid-like effects
• How its risks compare with 7-OH
• Whether the advertised ingredient is actually present

A scientific-sounding product label is not proof that a compound has been adequately studied.

The same principle applies to unfamiliar proprietary blends and newly introduced chemical names that have not yet appeared in peer-reviewed human research.

Consumers should not assume that an obscure name indicates a safer or more advanced alternative.

9. Experimental Synthetic Opioids: SR-17018, SR-15099, and SHR9352

Not every substance discussed as a 7-OH alternative is botanical or derived from kratom.

Some are laboratory-developed synthetic opioids originally investigated for pharmaceutical research.

SR-17018 and SR-15099

SR-17018 and SR-15099 belong to a group of experimental compounds studied for their activity at mu-opioid receptors.

Researchers have investigated whether certain receptor-signaling characteristics might influence pain relief, tolerance, or respiratory effects.

However, findings from laboratory and animal studies do not establish that these compounds safely treat opioid dependence in humans.

SR-17018 was included in federal emergency scheduling actions in August 2026.

SR-15099 is a distinct research compound and was not specifically named in that same order. Its omission does not automatically establish that every transaction involving it is lawful.

Neither compound is FDA-approved for opioid withdrawal or opioid use disorder.

Brooks previously examined their differences in SR-15099 vs. SR-17018: Experimental Opioids and Withdrawal Claims.

SHR9352

SHR9352 is another experimental synthetic opioid investigated for its receptor-signaling characteristics.

It emerged from research related to oliceridine, an opioid medication developed for certain acute pain applications.

SHR9352 itself has not received FDA approval.

Laboratory potency findings cannot establish safe human use or prove that it is an appropriate substitute for 7-OH, fentanyl, or another opioid.

Our article What Is SHR9352? Experimental Synthetic Opioid Research examines the evidence and limitations.

10. Tianeptine and Phenibut: Alternatives That Create Different Dependence Risks

Two additional substances deserve attention because they have historically circulated in overlapping supplement, nootropic, and convenience-store markets.

Neither should be described as an ordinary botanical extract.

Tianeptine Sodium and Tianeptine Sulfate

Tianeptine is a synthetic antidepressant prescribed in some countries outside the United States.

It also activates mu-opioid receptors and has been associated with tolerance, dependence, withdrawal, respiratory depression, and overdose.

Tianeptine sodium and tianeptine sulfate are different salt forms of the same underlying drug.

Online sellers sometimes promote sulfate as longer-lasting or less intense than sodium, but reliable direct human comparisons are limited.

Neither form is an FDA-approved treatment for opioid withdrawal.

People seeking to replace concentrated 7-OH with tianeptine may encounter another substance capable of producing opioid-like dependence.

Learn more about tianeptine sulfate vs. tianeptine sodium and their risks.

Phenibut

Phenibut is a synthetic compound that primarily affects GABA-related signaling.

It has been marketed as a nootropic, calming supplement, and anxiety-relief product.

Unlike tianeptine, phenibut’s primary pharmacological mechanism is not mu-opioid receptor activation.

Nevertheless, repeated use can result in significant physical dependence.

Withdrawal may involve severe anxiety, insomnia, agitation, hallucinations, and other potentially dangerous complications.

Someone already dependent on opioids should not assume that replacing 7-OH with phenibut is an effective or medically appropriate strategy.

Learn more in our article, What Is Phenibut? The Risks Behind This Anxiety Supplement.

Why “No 7-OH” Does Not Necessarily Mean “No Opioids”

One of the biggest misconceptions surrounding botanical blends involves labels that advertise the absence of a specific substance.

Consider a product that claims to contain:

No kratom. No mitragynine. No 7-OH.

Those statements may be accurate for the tested compounds and submitted sample.

However, they do not automatically establish that the product contains no other opioid-active substances.

MGM-15, MGM-16, and mitragynine pseudoindoxyl have chemical identities distinct from mitragynine and 7-OH.

A product could therefore test negative for one substance while containing another pharmacologically important compound.

The Buzzers investigation demonstrates why this distinction matters.

A certificate of analysis should identify the precise chemicals tested, the detection limits, and the batch represented.

Ideally, a comprehensive evaluation would also include appropriate testing for unknown ingredients and contaminants.

Even then, chemical testing cannot establish long-term safety, addiction potential, or effectiveness for treating withdrawal.

Those questions require appropriate pharmacological and clinical evidence.

Can Switching Botanical Blends Cause Withdrawal?

For individuals who have developed physical dependence on an opioid-active product, changing to another formulation may produce unexpected symptoms.

The explanation depends on the substances involved.

If someone has been regularly exposed to a potent opioid agonist and switches to a product with substantially less opioid activity, withdrawal may develop.

Conversely, switching to a product containing a stronger or unexpected opioid could increase the risk of intoxication or overdose.

Some compounds can also interfere with the effects of other opioids under specific conditions.

However, these mechanisms cannot be assumed simply because a person experiences sweating, anxiety, restlessness, or rapid heartbeat after changing products.

Such symptoms may reflect withdrawal, intoxication, medication interactions, or other medical conditions.

This is particularly important when a product’s exact ingredients are unknown.

For more information about managing dependence, read 7-OH Withdrawal: Symptoms, Timeline, and What Actually Helps.

Are Botanical Blends Legal in Tennessee?

The answer depends on the specific ingredients.

Tennessee’s kratom prohibition took effect July 1, 2026, and applies to the covered plant and kratom-derived products.

Federal authorities have also temporarily controlled several related opioid compounds, including MGM-15, MGM-16, and MGPI.

However, genuine botanical products containing kava, kanna, or other plants do not automatically fall under the same laws simply because they are marketed in the same retail category.

Legal questions become more complicated when products contain proprietary chemical mixtures, prohibited compounds, or substances subject to controlled-substance analogue provisions.

A retailer describing a product as “legal,” “compliant,” or “kratom-free” does not establish its status under every applicable law.

Consumers should not assume that online availability means possession or distribution is lawful in Tennessee.

Can Botanical Blends Cause Addiction or Overdose?

Some products marketed as botanical blends may contain compounds capable of causing physical dependence, substance use disorders, or life-threatening toxicity.

The risk depends on the actual ingredients, concentration, frequency of use, and other substances involved.

Products containing potent opioid agonists present particular concern for respiratory depression.

Warning signs of a possible opioid overdose include:

• Slow, shallow, or absent breathing
• Inability to wake the person
• Unusual snoring or gurgling sounds
• Blue or gray lips
• Extreme sedation or loss of consciousness

If an opioid overdose is suspected, call 911 and administer naloxone if available.

Naloxone can reverse opioid-mediated respiratory depression, although additional doses or other emergency interventions may be necessary.

For non-emergency concerns involving an unknown product or suspected poisoning, Poison Control is available at 1-800-222-1222.

Someone experiencing unexplained reactions should not attempt to correct the symptoms by taking additional tablets or switching to another unfamiliar blend.

Treatment for 7-OH, Botanical Blend, and Emerging Opioid Dependence

The rapid introduction of new substances presents a challenge for people who are already physically dependent.

A person may begin with kratom, move to concentrated 7-OH, and later encounter an alternative marketed under an unfamiliar botanical or chemical name.

Each change can introduce uncertainty about potency, ingredients, and withdrawal.

For people struggling to stop, the most appropriate approach begins with an individualized medical assessment.

Medical Detox

At Brooks Healing Center, medically supervised detox provides support for people experiencing withdrawal and related complications.

Clinical professionals assess the person’s substance use history, symptoms, other medications, and overall medical needs.

This is particularly relevant when someone has been using concentrated opioid-active products with uncertain formulations.

Medications for Opioid Use Disorder (MOUD)

Brooks also offers medications for opioid use disorder (MOUD) using FDA-approved medications when clinically appropriate.

For eligible individuals diagnosed with opioid use disorder, buprenorphine-based medications can help reduce cravings and manage withdrawal as part of a comprehensive treatment plan.

Available options include extended-release injectable buprenorphine medications such as Sublocade and Brixadi.

These medications are FDA-approved for opioid use disorder. They are not specifically approved to treat dependence on every individual botanical blend, kratom derivative, or experimental compound discussed in this article.

Treatment decisions must be individualized, especially when the exact substances involved are uncertain.

Residential Treatment and Recovery Support

For individuals experiencing compulsive use, repeated withdrawal, cravings, or significant disruption to daily life, residential addiction treatment may provide additional structure and support.

Brooks combines clinical care with counseling, recovery planning, and support for co-occurring mental health concerns when appropriate.

Continuing services include PHP, sober living, and alumni or peer support.

The goal is to help individuals establish stability without relying on an ongoing cycle of increasingly unfamiliar substances.

Frequently Asked Questions About Botanical Blends and 7-OH Alternatives

What are botanical blends?

Botanical blends are products containing one or more plant-derived ingredients. In the psychoactive-product market, the term is also used for proprietary tablets, extracts, and combinations marketed as alternatives to kratom or concentrated 7-OH. The exact ingredients vary considerably.

Is Botanical Blends a brand or a category?

Both uses exist. “Botanical blends” is a general description of products combining botanical ingredients, while Botanical Blends is also the name of an online retailer that lists brands such as Buzzers, Homiez, Fuzziez, and Shift.

Are botanical blends the same as 7-OH?

No. Genuine botanical preparations may have entirely different chemical and pharmacological properties. However, investigators have identified potent 7-OH-related opioids in certain products marketed using botanical terminology.

What botanical blends contain MGM-15?

Utah authorities confirmed MGM-15 and MGPI in tested Buzzers Cat’s Claw products. San Francisco investigators separately identified MGM-15 in a Script Botanicals × Maui Labs product associated with a fatal overdose. These findings do not establish that every product sold under those brands contains MGM-15.

Are Buzzers and Homiez dangerous?

Utah authorities confirmed dangerous opioid compounds in tested Buzzers products. Homiez was also named in a broader Poison Control warning about potentially adulterated botanical products. Product-specific evidence is necessary before attributing the confirmed Buzzers findings to every Homiez formulation.

What is the difference between Mitraxidine and 7-OH?

7-OH is a specific chemical compound, while Mitraxidine is marketed as a proprietary kratom-derived formulation. Its name alone does not establish its precise contents or prove equivalent effects, safety, or withdrawal characteristics.

Are kava and kanna safer than 7-OH?

Authentic kava and kanna have different pharmacological properties from concentrated 7-OH. However, both require consideration of their own adverse effects and medication interactions. There is insufficient evidence to establish either as a medically appropriate treatment for opioid dependence.

Can akuamma replace kratom?

Akuamma contains opioid-active alkaloids, but human research has not established that it safely treats kratom dependence or opioid withdrawal. Its botanical origin should not be interpreted as proof of safety or effectiveness.

What is 13-OH Corydalis?

The term appears in marketing for certain Corydalis-containing products. The designation does not establish a universally standardized formulation, and it should not be treated as chemically or clinically equivalent to 7-OH.

Are nano-tech mitragynine tablets safer?

There is insufficient clinical evidence demonstrating that commercially marketed nano-tech mitragynine tablets are safer than conventional formulations. Independent testing of one 7Stax sample identified both mitragynine and MGM-15, illustrating why ingredient verification matters.

Can switching botanical blends trigger withdrawal?

A change in exposure to opioid-active substances can potentially cause withdrawal in someone who is physically dependent. However, symptoms following a product change require medical evaluation because other pharmacological effects or medical problems may produce similar reactions.

Can botanical blends help someone quit 7-OH?

No commercially marketed botanical blend discussed here has been established as an FDA-approved treatment for 7-OH withdrawal or dependence. Individuals experiencing significant withdrawal should seek professional medical guidance rather than relying on unverified product substitutions.

Get Help for Kratom, 7-OH, and Botanical Blend Dependence at Brooks Healing Center

The market for botanical blends and 7-OH alternatives is changing faster than most consumers can reasonably follow.

Some products contain ordinary plant extracts. Others contain concentrated alkaloids, proprietary mixtures, or chemically manufactured opioids whose effects may be far different from what the packaging suggests.

The confirmed MGM-15 findings involving Buzzers, Script Botanicals, and an independently tested mitragynine tablet illustrate why product labels and unfamiliar ingredient names deserve scrutiny.

For people already experiencing dependence or withdrawal, the answer is not necessarily another product advertised as a safer replacement.

Brooks Healing Center provides addiction treatment between Nashville and Chattanooga in Normandy, Tennessee, including medical detox, residential treatment, medications for opioid use disorder (MOUD) when appropriate, PHP, sober living, and continuing recovery support.

Our team helps individuals navigate substance use involving kratom, concentrated 7-OH, synthetic opioids, and other emerging substances through individualized clinical assessments and treatment planning.

If you or someone you love is struggling with these products, CALL NOW: 931-486-8824 to speak confidentially with our admissions team.

You do not need to know the exact chemical name of a substance to recognize that its effects are becoming difficult to manage.

---

References

American College of Medical Toxicology. (2026). ACMT position statement: Public health concerns associated with 7-hydroxymitragynine and other kratom compounds. https://www.acmt.net/news/acmt-position-statement-public-health-concerns-associated-with-7-hydroxymitragynine-and-other-kratom-compounds/

American Kratom Association. (2026, September 29). Products purchased were “Smax” Pseudo-DHM — not natural kratom leaf. https://www.americankratom.org/news/products-purchased-were-smax-pseudo-dhm-tablets—-not-traditional-natural-kratom-leaf

Anresco Laboratories. (2026, March 19). Certificate of analysis: 7Stax 80 mg Raspberry Nano Tech tablet, sample 1391007, lot 2026-03 [Laboratory report]. TestMyKratom.org. https://www.testmykratom.org/reports/mit/1391007-7Stax-80mg-Raspberry-Nano-Tech-tablet.pdf

Botanical Blends. (2026, July 31). What moved into 7-OH shelf space in 2026. https://botanicalblends.shop/blogs/news/what-replaced-7-oh

National Center for Complementary and Integrative Health. (n.d.). Kava: Usefulness and safety. National Institutes of Health. https://www.nccih.nih.gov/health/kava

Angst, M. (2026, October 21). SF records first overdose death from a synthetic opioid sold at gas stations. The San Francisco Standard. https://sfstandard.com/2026/10/21/sf-records-first-overdose-death-synthetic-opioid-sold-gas-stations/

Tennessee Department of Mental Health and Substance Abuse Services. (2026). Emerging substances. https://www.tn.gov/behavioral-health/substance-abuse-services/prevention/emerging-substances.html

U.S. Department of Health and Human Services. (2026, October 9). HHS recommends science-based thresholds to target dangerous enhanced kratom products. https://www.hhs.gov/press-room/hhs-recommends-thresholds-enhanced-kratom-products-7-oh-mgpi.html

U.S. Department of Justice. (2026, October 9). Department of Justice announces updates to emergency scheduling actions for 7-OH and related opioid substances. https://www.justice.gov/opa/pr/department-justice-announces-updates-emergency-scheduling-actions-7-oh-and-related-opioid

U.S. Food and Drug Administration. (2024, December 18). FDA alerts industry and consumers about the use of Amanita muscaria or its constituents in food. https://www.fda.gov/food/hfp-constituent-updates/fda-alerts-industry-and-consumers-about-use-amanita-muscaria-or-its-constituents-food

U.S. Food and Drug Administration. (2026). Hiding in plain sight: 7-OH products. https://www.fda.gov/news-events/public-health-focus/hiding-plain-sight-7-oh-products

University of Utah Health, Utah Poison Control Center. (2026, July 22). Adulterated Cat’s Claw and kava products may cause opioid overdose. https://poisoncontrol.utah.edu/news/2026/07/adulterated-cats-claw-and-kava-products-may-cause-opioid-overdose

Utah Department of Agriculture and Food. (2026, July 30). Illegal kratom product sold in Utah County linked to death in Utah. https://ag.utah.gov/news/illegal-kratom-product-sold-in-utah-county-linked-to-death-in-utah/